Literature DB >> 4469193

Modulation of cell proliferation by macrophages: a possible function apart from cytotoxic tumour rejection.

R Keller.   

Abstract

The in vitro interaction between activated, non-immune macrophages (AM) and a variety of syngeneic, allogeneic or xenogeneic "normal" and "malignant" target cell lines was followed by different parameters such as target cell proliferation, viability or morphology.Proliferation of all rapidly replicating cell lines examined, irrespective of whether they were of syngeneic, allogeneic or xenogeneic origin, or showed normal or neoplastic growth characteristics, was similarly blocked by the presence of AM in an effector/target cell ratio of 10:1. It was only in very slowly proliferating cells that this inhibitory effect was not detectable. A marked diminution in target cell proliferation was also achieved with target cells growing in suspension, where maintenance of close contact between effectors and targets is unlikely, indicating that this macrophage effect may be mediated by a soluble product of AM.The finding of clear differences in the proliferation inhibition of slowly proliferating normal and neoplastic targets suggested that proliferation per se may not fully mirror the consequences of the macrophage/target cell interaction. This was affirmed when viability and morphology were used as parameters: viability was virtually unaffected in normal targets whereas neoplastic cells were killed.Accordingly, it is suggested that activated non-immune macrophages can affect targets in strikingly different ways. Inhibition of proliferation could be an important homoeostatic regulatory function of the macrophage which would affect every replicating cell. Cytocidal killing of targets, on the other hand, is achieved only on neoplastic cells.

Entities:  

Mesh:

Year:  1974        PMID: 4469193      PMCID: PMC2009319          DOI: 10.1038/bjc.1974.214

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  HOMOGRAFT TARGET CELLS: SPECIFIC DESTRUCTION IN VITRO BY CONTACT INTERACTION WITH IMMUNE MACROPHAGES.

Authors:  G A GRANGER; R S WEISER
Journal:  Science       Date:  1964-09-25       Impact factor: 47.728

2.  Mechanism of immunologically specific killing of tumour cells by macrophages.

Authors:  R Evans; P Alexander
Journal:  Nature       Date:  1972-03-24       Impact factor: 49.962

3.  Inhibition of spleen cell DNA synthesis by autologous macrophages.

Authors:  R M Parkhouse; R W Dutton
Journal:  J Immunol       Date:  1966-11       Impact factor: 5.422

4.  Role of activated macrophages and antibody in inhibition and enhancement of tumour growth in rats.

Authors:  R Keller; V E Jones
Journal:  Lancet       Date:  1971-10-16       Impact factor: 79.321

5.  Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance.

Authors:  J B Hibbs; L H Lambert; J S Remington
Journal:  Nat New Biol       Date:  1972-01-12

6.  Immunogenetic analysis of Ag-B histocompatibility antigens in rats.

Authors:  J Palm
Journal:  Transplantation       Date:  1971-02       Impact factor: 4.939

7.  Induction of immunity and tolerance in vitro in the absence of phagocytic cells.

Authors:  E Diener; K Shortman; P Russell
Journal:  Nature       Date:  1970-02-21       Impact factor: 49.962

8.  Endotoxin and double stranded RNA render macrophages cytotoxic.

Authors:  P Alexander; R Evans
Journal:  Nat New Biol       Date:  1971-07-21

9.  Antitumor effects of interferon preparations in mice.

Authors:  I Gresser; C Bourali
Journal:  J Natl Cancer Inst       Date:  1970-08       Impact factor: 13.506

10.  Regulation of lymphocyte responses in vitro. I. Regulatory effect of macrophages and thymus-dependent (T) cells on the response of thymus-independent (B) lymphocytes to endotoxin.

Authors:  M Yoshinaga; A Yoshinaga; B H Waksman
Journal:  J Exp Med       Date:  1972-10-01       Impact factor: 14.307

View more
  12 in total

1.  Macrophage activation by tuftsin and muramyl-dipeptide.

Authors:  M Bruley-Rosset; I Florentin; G Mathè
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

Review 2.  Tumor cells do not arise frequently.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  Production of macrophage-activating and migration-inhibition factors in vitro by serologically selected and cloned Listeria monocytogenes-specific T cells of the Lyt 1+2- phenotype.

Authors:  U Sperling; S H Kaufmann; H Hahn
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

4.  Analysis of therapeutic effect in experimental chemoimmunotherapy for rat ascites tumor.

Authors:  T Ogura; O Shinzato; M Sakatani; H Shindo; M Namba; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Infection of DBA/2 or C3H/HeJ mice by intraperitoneal injection of vaccinia virus elicits activated macrophages, cytolytic and cytostatic for S91-melanoma tumor cells.

Authors:  R J Natuk; J A Byrne; J A Holowczak
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Growth enhancing property of human monocytes from normal donors and cancer patients.

Authors:  L K Trejdosiewicz; A J Trejdosiewicz; N R Ling; P W Dykes
Journal:  Immunology       Date:  1979-05       Impact factor: 7.397

7.  The cytostatic activity of cultured Kupffer cells.

Authors:  K Pulford; R L Souhami
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

8.  Differential stimulation of murine lymphoma growth in vitro by normal and BCG-activated macrophages.

Authors:  C F Nathan; W D Terry
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

9.  Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties.

Authors:  N Matthews; J F Watkins
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640

10.  Giant-cell tumour of bone: cytological studies.

Authors:  K Kasahara; T Yamamuro; A Kasahara
Journal:  Br J Cancer       Date:  1979-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.